Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): The Newfoundland experience with 23 patients

Annals of Surgical Oncology

Volumn 16, Issue 7, 2009, Pages 1890-1895

  Hebbard, P C ^a   MacMillan, A ^b   Huntsman, D ^c   Kaurah, P ^c   Carneiro, F ^d   Wen, X ^d   Kwan, A ^a   Boone, D ^a   Bursey, F ^a   Green, J ^b   Fernandez, B ^b   Fontaine, D ^e   Wirtzfeld, D A ^f  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b Health Sciences Centre St John's   (Canada)

^c Hereditary Cancer Program   (Canada)

^d University of Porto   (Portugal)

^e Eastern Health Canada   (Canada)

^f UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; HEPARIN; UVOMORULIN;

ABDOMINAL ABSCESS; ADULT; ANASTOMOSIS LEAKAGE; ARTICLE; CANADA; CANCER SCREENING; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL PRACTICE; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; GENE MUTATION; HEREDITARY DIFFUSE GASTRIC CANCER; HUMAN; ILEUS; LUNG EMBOLISM; MALE; MOBILIZATION; MORTALITY; PATHOLOGY; PERCUTANEOUS DRAINAGE; PNEUMONIA; PORTAL VEIN THROMBOSIS; PREOPERATIVE CARE; PROPHYLACTIC TOTAL GASTRECTOMY; RETROSPECTIVE STUDY; SMALL INTESTINE OBSTRUCTION; SPLEEN INFARCTION; STOMACH BIOPSY; STOMACH CANCER; SURGICAL INFECTION; SURGICAL TECHNIQUE; TOTAL STOMACH RESECTION; URINARY TRACT INFECTION; VENOUS THROMBOEMBOLISM;

ADULT; CADHERINS; FEMALE; GASTRECTOMY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; NEWFOUNDLAND AND LABRADOR; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 67649185271     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0471-z     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-6.
2. Lauren P. The two histological types of gastric carcinomas: diffuse and so-called intestinal-type carcinoma. An attempt at histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
3. Henson DE, Dittus C, Younes M, et al. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128:765-70.
4. Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev. 1986;8:1-27.
5. Ekstrom AM, Serafini M, Nyren O, et al. Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: a population-based case-control study in Sweden. Int J Cancer. 2000;87:133-40.
6. Palli D, Galli M, Caporaso NE, et al. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev. 1994;3:15-8.
7. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402-5.
8. Suriano G, Yew S, Ferreira P, et al. Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res. 2005;11:5401-9.
9. Kaurah P, MacMillan A, Boyd, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 2007;297:2360-72.
10. Caldas C, Carneiro F, Lynch HT, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet. 1999; 36:873-80.
11. Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet. 2004;41:508-17.
12. Blair V, Martin I, Shaw D, et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol. 2006;4:262-75.
13. Barber M, Fitzgerald RC, Caldas C. Familial gastric cancer- aetiology and pathogenesis. Best Practice Res Clin Gastroenterol. 2006;20:721-34.
14. Carneiro F, Oliveira C, Suriano G, Seruca R. Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer. J Clin Pathol. 2008;61:25-30.
15. Pharoah PD, Guilford P, Caldas C for the International Gastric Cancer linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121:1348-53.
16. Hamy A, Letessier E, Bizouam P, et al. Study of survival and prognostic factors in patients undergoing resection for gastric linitis plastica: a review of 86 cases. Int Surg. 1999;84:337-43.
17. Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. NEJM. 2001;344:1904-9.
18. Carneiro F, Huntsman DG, Smyrk TC, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol. 2004; 203:681-7.
19. Barber M, Save C, Carneiro F, et al. Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk. J Pathol. 2008;216:286-94.
20. Norton JA, Ham CM, Dam JV, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg. 2007;245:873-79.
21. Lynch HT, Kaurah P, Wirtzfeld D, et al. Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy. Cancer. 2008;112:2655-63.
22. Moran CJ, Joyce M, McAnena OJ. CDH1 associated gastric cancer: a report of a family and review of the literature. Eur J Surg Oncol. 2005;31:259-64.
23. Lynch HT, Silva A, Wirtzfeld D, et al. Hereditary diffuse gastric cancer: prophylactic surgical oncology implications. Surg Clin North Am. 2008;88:759-78.
24. Richards FM, McKee SA, Rajput MH, et al. Germline E-cadherin gene (CDH1) mutations define an inherited cancer syndrome dominate by diffuse gastric cancer. Human Mol Genet. 1999;14: 249-55.
25. Charlton A, Blair V, Shaw D, et al. Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut. 2004;53:814-20.
26. Rogers WM, Dobo E, Norton JA, et al. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol. 2008;32:799-809.
27. Shaw D, Blair V, Framp A, et al. Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy? Gut. 2005;54:461-68.
28. van Kouwen MCA, Drenth JPH, Oyen WJG, et al. [18F]Fluoro-2- deoxy-D-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier. Clin Cancer Res. 2004;10:6456-9.
29. Nunobe S, Hiki N, Fukunaga T, et al. Laparoscopy-assisted pylorus-preserving gastectomy: preservation of vagus nerve and infrapyloric blood flow induces less stasis. World J Surg. 2007; 31:2335-40.
30. Ando S, Tsuji H. Surgical technique of vagus nerve-preserving gastrectomy with D2 lymphadenectomy for gastric cancer. ANZ J Surg. 2008;78:172-6.
31. Fein M, Fuchs K, Thalheimer A, et al. Long-term benefits of Roux-en-Y pouch reconstruction after total gastrectomy. Ann Surg. 2008;247:759-65.